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The hemolytic phospholipase C/sphingomyelinase PlcH from the opportunistic pathogen Pseudomonas
aeruginosa represents the founding member of a growing family of virulence factors identiﬁed in a wide
range of bacterial and fungal pathogens. In P. aeruginosa PlcH is co-expressed with a 17 kDa chaperone
(PlcR2) and secreted as a fully folded heterodimer (PlcHR2) of approximately 95 kDa, by the twin arginine
translocase (TAT) via the cytoplasmic membrane and through the outer membrane, by the Xcp (TypeII)
secretory system. PlcHR2 has been shown to be an important virulence factor in model P. aeruginosa
infections and is selectively cytotoxic, at picomolar concentrations to mammalian endothelial cells. Here
we report how the various challenges starting from protein overexpression in the native organism P.
aeruginosa, the use of detergents in the crystallization and data collection using the most advanced l-
focus synchrotron beam lines were overcome. Native diffraction data of this heterodimeric protein com-
plex were collected up to a resolution of 4 Å, whereas needle-shaped crystals of L-selenomethionine
substituted PlcHR2 with a maximum diameter of 10 micron were used to collect data sets with a max-
imum resolution of 2.75 Å.
 2012 Elsevier Inc. Open access under CC BY license.Introduction
Pseudomonas aeruginosa is an opportunistic bacterial pathogen
that poses a lethal threat to patients with open injuries and burn
wounds, immuno-compromised patients and above all, cystic
ﬁbrosis sufferers [1–3]. During infection the pathogen produces
and secrets a variety of virulence factors including Exotoxin A,
and at least four different phospholipases C (PLC) [4,5] including
the recently discovered P. aeruginosa phospholipases PlcA and PlcB
that belong to the well-characterized family of Zn-dependent PLCs
[4]. The biological functions of these PLCs however, are not well
understood, although PlcB has been shown to be required in the
chemotaxis of P. aeruginosa towards phospholipids (e.g. phosphati-
dylcholine a major component of lung surfactant) [4,6]. Two extra-
cellular PLCs of P. aeruginosa were identiﬁed earlier [7]. These are
the hemolytic phospholipase C (PlcH) and its closely related non-
hemolytic ortholog PlcN, which are almost twice as large as PlcA
and PlcB, respectively, and show no signiﬁcant sequence similarity
to the Zn-dependent class of PLCs [5,8]. PlcH is co-expressed withtwo in-phase overlapping genes plcR1/plcR2 that are located down-
stream to the plcH gene. The 23 KDa PlcR1 and the 17 kDa PlcR2 are
believed to act as co-chaperones in the secretion of PlcH by form-
ing heterodimeric PlcHR1 and PlcHR2 complexes [9]. These com-
plexes are secreted into the extracellular environment in a folded
state via the twin-arginine translocation (TAT) pathway through
the inner membrane [10,11] and subsequently through the lipo-
polysaccharide containing outer membrane of P. aeruginosa via
the Xcp (Type II) system [5].
More recently it has become clear that PlcH is the prototype of a
growing superfamily of enzymes, which include a range of extra-
cellular toxins with phospholipase C and sphingomyelinase activi-
ties. Consequently, PlcH does not merely represent a single
extracellular virulence factor produced by only a single opportu-
nistic pathogen. In fact, some fungal and numerous bacterial
pathogens express one or more multiple orthologs. For example,
Aspergillus fumigatus caries one PlcH ortholog [12], individual Burk-
holderia pseudomallei possess three genes encoding PlcH orthologs
[13] and some Mycobacterium tuberculosis strains express as many
as 4 different orthologs [14]. The emerging opportunistic pathogen
Acinetobacter baumannii, as well as the Select Agent Burkholderia
mallei each carry two genes encoding members of PlcH superfamily
[15]. Finally, there is one member of this superfamily with a known
crystal structure, AcpA from Francisella tularensis, which, based on
sequence comparison would be situated just at the evolutionary
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enzymes, which only have phosphatase activity [16]. AcpA, which
shares approximately 22% sequence identity with the catalytic do-
main of PlcH is a periplasmic protein with acid phosphatase activ-
ity that can utilize an assortment of biologically important
phosphorylated compounds (e.g. ATP and tyrosine-PO4) [17].
The PlcHR2 complex secreted by P. aeruginosa has profound bio-
logical functions as summarized below. First of all, the enzyme has
been shown to be highly active on sphingomyelin, as well as phos-
phatidylcholine, but it is much less active on other phospholipids
that do not contain choline (e.g. phosphatidylethanolamine, phos-
phatidylglycerol), and it is not active on phosphatidylserine [18].
Accordingly PlcHR2 catalyzes the hydrolysis of sphingomyelin to
phosphocholine and ceramide, as well as it hydrolyzes phosphati-
dylcholine to phosphocholine and diacylglycerol (DAG) [19]. Cera-
mide and DAG are important eukaryotic secondary messenger
molecules implicated in a wide array of functions ranging from
inﬂammation to apoptosis [20], but remarkably they exert very
distinct effects. For example, generation of ceramide from sphingo-
myelin is pro-apoptotic while increased production of DAG induces
a proliferative or transformation response in eukaryotic cells. It is
important to note in this regard that this enzyme exhibits a highly
selective cytotoxicity to human endothelial cells [12].
The three-dimensional structure of PlcHR2 will help to decipher
the catalytic mechanism and hence inform about the molecular ba-
sis of enzymatic activity and endothelial cell interactions (e.g.
binding to integrin receptors). Crystallographic studies on PlcHR2,
however, are hampered by a multitude of difﬁculties on several
levels. To start with, Escherichia coli has a signiﬁcantly lower
G + C content than P. aeruginosa (50% vs 67%) and it lacks a func-
tional Xcp secretory system [21]. Accordingly, the PlcHR2 complex
is much more efﬁciently translated and the heterodimeric complex
is secreted as soluble protein into the extracellular compartment
(i.e. culture supernatant), using the native P. aeruginosa expression
system. Moreover, although PlcHR2 itself is not a membrane pro-
tein its substrates are membrane associated, hence the protein
shows a high degree of afﬁnity for phospholipids and membrane
structures further exacerbating puriﬁcation as well as crystalliza-
tion. Finally, L-selenomethionine substituted protein had to be pro-
duced in order to solve the crystallographic phase problem.
Here we describe the methods we developed to overcome the
intrinsic problems towards obtaining diffracting crystals. These in-
clude: (i) the optimization of protein preparation, (ii) the develop-
ment of an over-expression system in a methionine auxotroph to
produce L-selenomethionine substituted protein samples and (iii)
the use of additives and detergents for crystal optimization. Finally,
we present the usage of the l-focus beam line X06SA at the Swiss
Light Source (SLS) that enabled us to collect a complete diffraction
data set to 2.75 Å resolution using crystals with dimensions of less
than 10 lm. The strategies and methods we describe here are
applicable to the challenges protein crystallographers face today
and in the future.Materials and methods
Protein expression in P. aeruginosa, puriﬁcation and characterization
Our efforts were focused on the native PlcHR2 protein complex
as the most stable and soluble complex [19]. Due to the fact that
the protein failed to localize extracellularly in recombinant E. coli
expression systems, we resorted to expression in the environment
of its natural host as previously described [8]. Brieﬂy, the protein
was overexpressed in P. aeruginosa strain PA01 derivative
ADD1976 carrying a chromosomal T7 polymerase gene under the
control of the lacUV5 promoter. The expression of plcHR2 is con-trolled by the T7 promotor on the pADD3268 vector. P. aeruginosa
was grown at 37 C in minimal M9 media to an optical density of
OD590  0.6, induced with isopropylthio-b-galactopyranoside
(IPTG) and then kept at 32 C for an additional 12 h during aeration
of the culture. The use of 32 C is based on the temperature typi-
cally used for optimal expression of extracellular factors of P. aeru-
ginosa [22] and hence no increase of protein yield was observed at
30 C or 37 C (unpublished results). Cells were ﬁrst separated from
the supernatant by centrifugation at 10,000g. Then 1.5 times vol-
ume of cold ddH2O was added to the supernatant containing
PlcHR2 in order to reduce ionic strength before applying the solu-
tion to micro granular anion exchanger diethylaminoethyl cellu-
lose DE52. The protein was eluted with 500 mM NaCl and after
further concentration and dialysis applied to a BioRad Model 491
prep cell which was used to separate culture supernatant proteins
by continuous elution native gel electrophoresis (7.5% non-dena-
turing polyacrylamide). The prep cell was run at constant power
of 12 W, and protein fractions were eluted at pH 7.2 with a ﬂow
rate of 0.35 ml/min. Separated proteins were delivered to a fraction
collector and pooled in 2 ml fractions. Peak fractions were pooled,
concentrated and frozen at 80 C. All puriﬁcation procedures
were carried out at 4 C. Successive matrix-assisted laser desorp-
tion ionization (MALDI) and electron spray mass spectrometric
analysis (ESI-MS) conﬁrmed the identity of the heterodimeric
PlcHR2 complex as reported earlier [8]. The overall yield was im-
proved to 1.6 mg/l culture by increasing the aeration after IPTG
induction.
L-Selenomethionine substituted protein
The plcHR2 genes were expressed in the same native P. aerugin-
osa T7 expression system [8] with the important addition that the
metZ gene in P. aeruginosa PAO1 ADD1976 was mutated using eth-
ylmethansulfonate (EMS). Thus, this strain is no longer capable of
L-methionine biosynthesis. The mutation (TGG to TAG leading to
TrpSTOP) in themetZ gene was veriﬁed by sequencing of PCR prod-
ucts from the ampliﬁed gene in this strain. For L-selenomethionine
substituted protein production, the plcHR2 genes were expressed
in minimal media with L-selenomethionine at 50 lg/ml. The pro-
tein was puriﬁed using the same protocols described above. The
yield was signiﬁcantly lower compared to the native protein with
approximately 0.6 mg/l culture.
Crystallization of the native PlcHR2
Initial crystallization experiments were performed with native
PlcHR2 in various buffer compositions and concentrations, how-
ever the most promising initial results were obtained with the pro-
tein at 1.5 mg/ml in 50 mM Tris pH 7.4, 50 mM NaCl, 0.1 mM TCEP.
Early crystallization screens using standard manual vapor diffusion
setup and commercially available screens [23] led to two crystal
morphologies. The ﬁrst crystals were obtained with 10% dioxane,
0.1 M MES buffer, pH 6.5 and 1.65 M ammonium sulfate (AS).
The second crystal form was obtained with 30% PEG3350, 70 mM
BisTris, pH 6.5 and 0.45 AS. Crystallization optimization strategies
ranged from different experimental set-ups including hanging and
sitting drops at different temperatures, batch crystallization, to the
addition of commercially available and in-house additive screens.
Tungstate and vanadate were used as these anions have been suc-
cessfully used in crystallization where they occupy phosphate sites
[24]. Because PlcHR2 has a high afﬁnity for membranes (i.e. phos-
pholipids) and therefore behaves like a membrane associated pro-
tein, the membrane protein additive screen was used to improve
crystal reproducibility and quality [25]. The best native crystals
were obtained with the protein concentrated to approximately
9 mg/ml in sitting drop vapor diffusion experiments with a reser-
Fig. 1. SDS–PAGE analysis of puriﬁed Pseudomonas aeruginosa PlcHR2 showing two
distinct bands for the separated PlcH and the PlcR2 proteins.
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drop was setup with 2 ll protein solution and mixed with 0.7 ll
reservoir solution and 0.3 ll 300 mM zwittergent.
L-Selenomethioine substituted PlcHR2
Initially crystallization was attempted using conditions close to
those that were successful with the native PlcHR2 sample, how-
ever, no crystals were obtained with the dioxane containing solu-
tion. The condition based on PEG3350 led to a large number of
very small crystals that typically showed multiple diffraction pat-
terns to a maximum resolution of approximately 5 Å. In order to
deal with the extensive nucleation observed in many drops various
seeding techniques were employed [26]. The best crystals were ob-
tained with a protein solution at 9 mg/ml in 50 mM Tris pH 7.4,
50 mM NaCl, 0.1 mM TCEP ﬁltered through a 0.22 lm ﬁlter and
centrifuged for ten minutes. The crucial step in reproducibly
obtaining crystals was streak-seeding using a cat-whisker frommi-
cro-crystals obtained under similar conditions.
Diffraction experiments
The ﬁrst native crystals were tested at the EMBL Hamburg out-
station wiggler beam line BW7B [27] located at the 2nd generation
synchrotron DORIS at DESY. All consecutive diffraction experi-
ments were performed at the 3rd generation synchrotron, the
Swiss Light Source (SLS). Experiments were performed either on
beam line X10SA which features a focused beam size of
50  10 lm [28,29] or in case of L-selenomethionine substituted
PlcHR2 on the l-focus beam line X06SA. This beam line is equipped
with the high-precision microdiffractometer MD2 and allows a fo-
cus of 25  6 lm [30]. The small beam focus matches the size of
these protein crystals much better, which signiﬁcantly increases
signal-to-background ratio.
Native protein crystals were typically ﬁshed directly from the
drop using standard nylon loops and frozen in the cold nitrogen
stream [31]. L-selenomethionine substituted crystals were extre-
mely fragile and hence mounting only succeeded using MiTeGen
MicroLoops E which also showed the lowest background on the
diffraction pattern [32]. All diffraction data were collected using
the rotation methods with crystals cooled to 100 K.
Indexing, integration and scaling
All diffraction data were carefully indexed, integrated and
scaled using XDS [33] and/or HKL2000 [34].Results and discussion
High-yield expression and puriﬁcation
Using P. aeruginosa as the natural host we were able to obtain
mg amounts of pure and active PlcHR2. The single step puriﬁcation
resulted in >99% pure protein as judged from SDS PAGE analysis
(Fig. 1) suitable for crystallization. L-selenomethionine substituted
protein was expressed and puriﬁed in order to obtain crystals suit-
able to solve the crystallographic phase problem using MAD tech-
niques [35]. The expression was thus successfully adapted by
disrupting the inherent methionine pathway to incorporate L-sele-
nomethionine from the medium. Although L-selenomethionine
containing proteins have been expressed in the past in an auxotro-
phic P. aeruginosa strain [36], as well as Pseudomonas ﬂuorescence
[37], the method described here is tailor-made for the expression
of extracellular virulence of P. aeruginosa that may be toxic for
other expression hosts. ESI-MS analysis was used to verify thatboth components (PlcH and PlcR2) are present in the complex,
and to assess the level of L-selenomethionine substitution. Given
the size of the complex and the likely heterogeneity of substitution
the molecular masses are not expected to be very accurate, how-
ever, peaks at 16,878 Da, 16,925 Da and 16,996 Da may correspond
to the 1-, 2-, and 3-fold substitution of methionine by L-selonome-
thionine (mass difference 47 Da) in PlcHR2 (ESI-MS of the native
protein 16,831 Da). In addition, there is a series of peaks with
molecular weight of 78,706 Da, 78,745 Da and 78,800 Da, which
may represent 7-, 8-, and 9-fold substitution with an expected
molecular weight of 78,386 Da the unmodiﬁed PlcH. (Fig. S1 in
Supplementary material).
Crystallization
Native PlcHR2 crystals typically grew over a period of 1–
2 months with maximum dimensions up to approximately
20  100  100 lm3 (Fig. 2a). Although the crystals were highly
reproducible diffraction properties of crystals differed signiﬁcantly
not only from protein batch to batch but also between crystals
from the same crystallization tray. L-selenomethionine substituted
crystal grew typically for a period of 2 months to thin needles of
maximal dimensions of 10  10  200 lm3. These crystals were
hardly visible in sitting drop trays (data not shown) and proved
to be extremely fragile (Fig. 3).
All attempts to increase diffraction quality of either native pro-
tein or L-selenomethionine substituted crystals by the various
post-crystallization techniques including various stabilizing solu-
tions [38], dehydration and crystal annealing [39–41] did not im-
prove diffraction properties and more often than not quickly
destroyed the crystals.
Diffraction experiments
Although the crystal diffracted to reasonable resolution on the
SLS beam lines, radiation damage poses a major challenge [42]. Na-
tive PlcHR2 crystals typically showed noticeable signs of severe
damage after less than 30 s of exposure. However, due to the rela-
tive large crystal size compared to beam focus complete data sets
Fig. 2. (a) Native crystals of PlcHR2 with approximate dimensions of 100  100  20 lm in the crystallization droplet. The scale bar represent approximately 100 lm.(b)
Typical native crystal mounted in a nylon loop on the high-resolution diffractometer of beam line X10SA [29].
Fig. 3. L-selenomethioine crystals mounted on the microdiffractometer MD2 at
beam line X06SA. The red ellipsoid corresponds to the focused beam size of
25  6 lm (Full width at half maximum).
Fig. 5. Diffraction pattern of a L-selenomethioine PlcHR2 crystal. The edge of the
detector corresponds to approximately 2.5 Å resolution.
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The best diffraction was recorded to a Bragg spacing of about
3.5 Å, the diffraction data however are anisotropic with signiﬁ-
cantly higher mosaicity and lower resolution in one direction
(Fig. 4).
The L-selenomethionine crystals diffracted surprisingly well to a
maximum Bragg spacing of 2.5 Å (Fig. 5). However, these crystals
proved to be much more radiation sensitive. Due to the higher
cross-section of selenium compared to sulfur in particular on theFig. 4. Diffraction pattern of a native crystal. Diffraction spots are clearly visible
beyond the water ring at approximately 3.5 Å resolution.peak of the absorption edge, the crystals absorb more strongly
and hence deteriorate much quicker. Clear signs of radiation dam-
age were visible after 3 s of exposure with the full beam and hence
a maximum of 20 of rotation only could be collected by careful
attenuation. Beam attenuation of more than 50% led to an unusable
weak diffraction pattern. In order to collect a complete data set the
crystals were shifted manually by approximately 20 lm along the
longest needle dimension after 20 of rotation. For each of these
20 sweeps the crystal position was optimized manually by diffrac-
tion-based alignment. This was of particular importance in the po-
sition where the loop was oriented in the plane of the on-axis
microscope. The best diffraction data were obtained by this manual
mode of helical data collection where the effects of radiation dam-
age are mitigated by exposing a fresh part of the needle before the
exposed part has already been completely destroyed. Helical data
collection modes have been automated at the ESRF and the Dia-
mond Light Source where the starting and end points for transla-
tion can be picked by the user and the optimal translation for a
given oscillation range is calculated [43,44].
The optimal wavelength for data collection on L-selenomethio-
nine substituted crystals was determined by performing an X-ray
emission ﬂuorescence scan which clearly indicated the optimal en-
ergy for the collection of single-anomalous diffraction (SAD) phas-
ing (Fig. 6). The scan also conﬁrmed the incorporation of L-
selenomethionine in place of methionine, at sufﬁcient levels for
structure solution. Data statistics from the highest resolution data
sets are summarized in Table 1.
Table 1
Data collection and processing parameter.
Native PlcHR2 Se-Met PlcHR2
Beam line X10SA X06SA
Wavelength [Å] 1.000 0.95370
Temperature [K] 100 100
Oscillation range [] 1 1
No. of frames 180 170
Unit cell dimensions [Å], [] 175.5, 196.4,
325.3
157.9, 75.4, 141.0,
b = 93.2
Space group C2221 C2
Max. resolution [Å] 4.0 2.75
No. of observed reﬂections 150 089 150 083
No. of unique reﬂections 45 739 43 080
Completeness (last shell) 95.6 (92.2) 99.7 (99.3)
Rsym
a(last shell) 0.103 (0.352) 0.130 (0.308)
I/r (last shell) 8.3 (2.7) 9.3 (4.7)
a R = SUM(I  <I>)2/SUM(I2).
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The native protein crystallized in the orthorhombic space group
C2221 with unit cell dimensions of a = 175.5, b = 196.4, and
c = 325.3 Å. Given the limited diffraction properties it is reasonable
to assume a higher than average solvent content which leads to be-
tween four and six PlcHR2 complexes in the asymmetric unit. Six
complexes would translate to a solvent content of 50% with a Mat-
thews factor of 2.46 Å3/Da whereas four molecules results in 67%
solvent content and VM = 3.7 Å3/Da [45,46]. The L-selenomethio-
nine substituted protein crystallized in a much smaller unit cell
with space group C2 and a = 158.4, b = 74.3, and c = 141.4 Å,
b = 93.2. The asymmetric unit is most likely to contain two inde-
pendent complexes with a solvent content of 43% and
VM = 2.2 Å3/Da. The smaller unit-cell and the lower solvent content
may explain the better diffraction properties of these crystals com-
pared to the native protein.Molecular replacement
Structure solution attempts by molecular replacement were
performed with a number of programs but mainly using PHASER
[47] and Phenix/Rosetta [48]. Initial trials used the native data,
but later when the higher resolution L-selenomethionine crystals
became available the best data set as given in Table 1 was used.
Several reduced search models based on the phosphodiesterase do-
main of the crystal structure of AcpA were constructed. Models
were limited to the most similar part by removing all insertions
and to the least ﬂexible model where all ﬂexible loops were also
taken out. Models included multi-alanine structures where all res-
idues that are different were changed to alanines and poly-alanine
models. In addition, a second search fragment based on a very low
similarity of the C-terminal domain-of-unknown function with the
IG-like domain of human carcinoembryonic antigen cell adhesion
molecule (pdb-code: 2DKS) was constructed and molecular
replacement with two models was attempted. In spite of exhaus-
tive efforts no convincing structure solution was obtained. It
should be noted that given the low sequence identity of the search
fragment constituting only about half of the scattering mass and
the overall quality of the diffraction data this failure of molecular
replacement trials had to be expected.Fig. 6. Typical ﬂuorescence emission scan recorded from a L-selenomethionine PlcHR2
[49].Anomalous data and MAD phasing
In spite of the small crystals size (Fig. 3) the ﬂuorescence emis-
sion scan depicted in Fig. 6 showed a clear signal and unambigu-
ously conﬁrmed the substitution of methionine by L-
selenomethionine. However, due to the severe radiation damage
it was not possible to collect diffraction data at more than one X-
ray energy from a single crystal. Even the highest resolution and
most complete data set collected from one crystal at the high-en-
ergy remote wavelength (summarized in Table 1) resulted in a rel-
atively low overall I/r(I) of 9.3 with an Rsym of 0.13. Considering the
additional low crystallographic symmetry, which inherently re-
sults in low redundancy, it is no surprise that even at low resolu-
tion no useful anomalous signal was detected and the sub-
structure of Se-positions could not be determined. Further data
sets were collected from other crystals at the peak and inﬂection
point determined by the ﬂuorescence emission. The optimization
of scaling procedures is currently underway in order to construct
a useful 3-wavelength data set that will enable to solve the phase
problem in the near future.Conclusions
In this paper we describe signiﬁcant progress towards the crys-
tal structure determination of the PlcHR2 complex from P. aerugin-crystal on beam line X06SA. The values for f0 and f00 were calculated with CHOOCH
D. Truan et al. / Protein Expression and Puriﬁcation 90 (2013) 40–46 45osa. Diffracting crystals of the native protein were obtained with
detergents typically used for the crystallization of membrane pro-
teins. However, since molecular replacement trials with native
data to medium resolution failed, novel methods to over-express
and purify L-selenomethionine substituted protein from its natural
source P. aeruginosa were developed. These methods will have
wider application for proteins that are less amenable for recombi-
nant overexpression in E. coli due to toxicity and the typical inabil-
ity of that organism to secret extracellular proteins. Further
crystallization and the application of seeding techniques led to L-
selenomethionine substituted micro-crystals that diffracted, albeit
weakly to better than 2.5 Å resolution. Diffraction to this high res-
olution could only be recorded using the leading l-focus beam
lines highlighting once again the impact of 3rd generation synchro-
tron sources on macromolecular crystallography. Due to the lim-
ited crystal size and radiation sensitivity, the best crystals
resulted in a data set to a resolution of 2.75 Å. Molecular replace-
ment attempts have failed also for the higher resolution data set
obtained from L-selenomethionine substituted crystals, presum-
ably due to a combination of limited data quality and the lack of
a sufﬁciently similar search model for structure solution. Success-
ful structure solution will therefore require the application of im-
proved data collection methods including optimized mounts for
crystal positioning and the helical method where the crystal is ro-
tated and shifted along the longest crystal dimension to minimize
and smoothen the effects of radiation damage. Improved scaling
procedures will help to merge data collected from different crystals
in order to obtain a complete single-anomalous or if possible mul-
tiple anomalous data set required to solve the crystallographic
phase problem.
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